Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...
Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
On May 5, 2025, Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as an interchangeable biosimilar to the reference product ...
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...
Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...
The approval was based on a totality of evidence, including data from a phase 3 study (ClinicalTrials.gov Identifier: NCT04967508) that compared the efficacy and safety of Pyzchiva to the reference ...
This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results